Relapsed Or Refractory Multiple Myeloma clinical trials

Explore recruiting relapsed or refractory multiple myeloma clinical trials.

Recruiting relapsed or refractory multiple myeloma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Relapsed Or Refractory Multiple Myeloma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP 101 in Patients with Plasma Cell Disorders Including Multiple Myeloma

Hungary, Poland, Germany, Romania, Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Italy, Austria, Germany, Hungary, Spain, Norway +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Study to Evaluate Safety, Pharmacokinetics, and Activity of Cevostamab as Monotherapy and Cevostamab Plus Pomalidomide and Dexamethasone or Cevostamab Plus Daratumumab and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (CAMMA 1)

France, Czechia, Italy, Spain, Denmark, Poland

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma

Spain, Italy, Denmark, France, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

Relapsed Or Refractory Multiple Myeloma trials by city

Relapsed Or Refractory Multiple Myeloma in Toronto Relapsed Or Refractory Multiple Myeloma in Vancouver Relapsed Or Refractory Multiple Myeloma in Montreal Relapsed Or Refractory Multiple Myeloma in Calgary Relapsed Or Refractory Multiple Myeloma in Edmonton Relapsed Or Refractory Multiple Myeloma in Ottawa Relapsed Or Refractory Multiple Myeloma in Winnipeg Relapsed Or Refractory Multiple Myeloma in Quebec City Relapsed Or Refractory Multiple Myeloma in Hamilton Relapsed Or Refractory Multiple Myeloma in Kitchener Relapsed Or Refractory Multiple Myeloma in London Relapsed Or Refractory Multiple Myeloma in Halifax Relapsed Or Refractory Multiple Myeloma in New York Relapsed Or Refractory Multiple Myeloma in Los Angeles Relapsed Or Refractory Multiple Myeloma in Chicago Relapsed Or Refractory Multiple Myeloma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease